MétaCan
Menu
Back to cohort
Record W2035440823 · doi:10.1080/080370500439326

Study on COgnition and Prognosis in the Elderly (SCOPE): Design and Objectives

2000· article· en· W2035440823 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueBlood Pressure · 2000
Typearticle
Languageen
FieldMedicine
TopicBlood Pressure and Hypertension Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineCandesartanTolerabilityBlood pressureDementiaStroke (engine)Internal medicinePlaceboCognitive declineCardiologyMyocardial infarctionPhysical therapyAdverse effectAngiotensin IIDisease

Abstract

fetched live from OpenAlex

Hypertension is a major risk factor for cardiovascular events, including stroke, as well as for white matter lesions of the brain. There is also evidence to link cognitive impairment and dementia to hypertension. However, it has not been established whether antihypertensive treatment of elderly patients with a diastolic blood pressure (DBP) in the range 90-99 mmHg provides protection against major cardiovascular events and cognitive impairment. The Study on COgnition and Prognosis in the Elderly (SCOPE) is the first study designed to assess the effects of antihypertensive drug treatment on major cardiovascular events and cognitive function in elderly patients with mild hypertension. SCOPE is a prospective, randomized, double-blind, parallel comparison of the effects of the angiotensin II type 1 (AT 1 ) receptor blocker candesartan cilexetil and placebo on major cardiovascular events (myocardial infarction [MI], stroke and cardiovascular death), cognitive function as measured by the Mini-Mental State Examination (MMSE), quality of life (QoL) and health economics. The study has included both men and women, aged 70-89 years of age, with systolic blood pressure (SBP) of 160-179 mmHg and/or DBP of 90-99 mmHg and an MMSE score of 24 or above. Nearly 5000 patients have been recruited and will be followed for a mean period of 2.5 years. After a run-in period of 1-3 months, patients were randomized to receive placebo or candesartan cilexetil, 8 mg once daily, which has been shown to provide effective and long-lasting blood pressure reductions, while maintaining placebo-like tolerability, in elderly patients. All previous antihypertensive treatment was standardized to hydrochlorothiazide (HCTZ), 12.5 mg, at enrolment. At any time during the study, the dose of study drug will be doubled if SBP rises above 160 mmHg or DBP rises above 85 mmHg. If an SBP above 160 mmHg or a DBP above 90 mmHg is observed despite the increase in study medication, additional antihypertensive medication with HCTZ is recommended. Assessments to be made during the study will include blood pressure, heart rate, ECG, MMSE, health economics and QoL. Data on adverse events and clinical events will also be collected throughout the study. SCOPE is organized and co-ordinated by an Executive Committee, a Steering Committee, an Independent Safety Committee, an Independent Event Committee and a Co-ordinating Centre. Countries participating in the Study include Belgium, Canada, Finland, France, Germany, UK, Hungary, Israel, Norway, Poland, Portugal, Spain, Sweden, The Netherlands and the USA. Inclusion of patients was completed in January 1999 and at that time 4964 patients were randomized. The baseline characteristics of these patients are shown in the Table.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.575
Threshold uncertainty score0.358

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.280
Teacher spread0.241 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it